European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Real-world outcomes of stage III NSCLCs managed by surgery or definitive radiation therapy in the era of immunotherapy.
Etienne Abdelnour-Berchtold, Louis-Emmanuel Chriqui, Laetitia Zermatten, Sotirios Papadopoulos, Celine Forster, Arpad Hasenauer, Benoit Bedat, Matthieu Zellweger, Remy Kinj, Nuria Mederos, Michel Christodoulou, Alfredo Addeo, Frederic Triponez, Wolfram Karenovics, Michel Gonzalez
Published: 202610.1016/j.ejso.2026.111401
Abstract
OBJECTIVES: Immunotherapy (IO) has been associated with better outcomes in locally advanced non-small cell lung cancers (NSCLCs). In 2017, our center introduced compassionate use of immunotherapy for stage III NSCLC as follows: neoadjuvant chemothera…
Preview only. Read the full abstract at the source